NeuroSense Therapeutics Ltd. fell 10.1% on Wednesday, November 11, 2026, on 51,900 shares. No headline about NRSN came out that day or the day before in the news feeds we follow, so the move may come from news we don't track, the sector or trading alone.
NeuroSense Therapeutics Ltd. (NRSN:NASDAQ) closed at $1.57 on November 16, 2026, down 7.40% on the day. The stock trades 93.8% below its 52-week high of $25.40 and 42.3% above its 52-week low of $1.10. Over the past year, it lost 93.7%. NeuroSense Therapeutics Ltd. is part of the Health Care sector.
In 252 trading sessions since November 14, 2025, NRSN closed higher on 103 days (41%). Its best day was September 4, 2026 (+27.11%) and its worst was November 2, 2026 (-28.14%). The stock moved 10% or more in a single session 26 times. It opened at least 5% above the previous day's high 1 time.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its lead product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
Find more stocks like NRSN with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.